RCT of Behavioral Activation for Depression and Suicidality in Primary Care
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Depression
- Sponsor
- VA Office of Research and Development
- Enrollment
- 140
- Locations
- 3
- Primary Endpoint
- Change From Baseline in Depressive Symptoms at 12 Weeks
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
The purpose of the Improving Mood in Veterans in Primary Care (IIR 14-047) is to evaluate a brief educational individual workshop that is meant to help Veterans better understand feelings of sadness and ways to improve their mood. This study is intended to evaluate and establish the workshop's effectiveness for use with Veterans in primary care settings.
The study involves up to 6 in-person meetings and 6 telephone interviews across a 6-month period of time. Approximately 144 Veterans will participate in the study. Using a procedure like the flip of a coin, the participants will have a one in two chance of receiving the brief educational workshop or treatment as usual condition.
Detailed Description
Background: Depressive symptoms are the most common referral problem to integrated mental health providers within Veteran primary care clinics. Although there exist several empirically-based brief psychotherapies for depression in primary care, the most significant barrier to providing those psychotherapies is treatment duration (e.g., the treatments range from 6-8 sessions of 30-50 minutes) as it does not match typical treatment formats delivered by mental health providers working in primary care (i.e., 1-4 15-30 minute sessions). Therefore, this HSR\&D study titled, RCT of Behavioral Activation for Depression and Suicidality in Primary Care, will examine the effectiveness of a brief version of an existing efficacious longer treatment for depression, called behavioral activation. Objectives: The overarching objectives of this study are to: 1) examine whether a 4-session manualized behavioral activation intervention (BA-PC) compared to Treatment as Usual (TAU) is effective in reducing self-reported depressive symptoms and subjective secondary outcomes such as sleep impairment and quality of life; 2) examine patient satisfaction, engagement, and receptivity to a 4-session BA-PC; and 3) explore the impact of BA-PC on suicidal ideation. Methods: The study will achieve these objectives using a randomized, controlled trial study design that has two conditions (4-session BA-PC and Treatment as Usual). Veterans will be recruited from three VA primary care settings in the Western portion of VISN 2 (Syracuse, Rochester, and Buffalo). The primary inclusion criteria for the study will be a report of depressive symptoms by primary care patients, who are not currently engaged in psychological treatment for depression. A total of 136 Veterans will be targeted for randomization. All Veterans will be assessed every 2 weeks for changes in mood and more comprehensive assessments will be completed at 6, 12, and 24 weeks. Status: Recruitment has ended as of 2/26/18 with 140 participants being randomized. Follow-up will continue for another 24 weeks. We are preparing the data for analysis.
Investigators
Eligibility Criteria
Inclusion Criteria
- •aged 18 years
- •seeking or receiving primary care services at the Syracuse, Canandaigua, or Buffalo VA Medical Centers
- •reporting at least moderate depressive symptoms
- •stable course of antidepression medications
- •stable course of outpatient treatment for anxiety or substance use disorders
Exclusion Criteria
- •Veterans who are:
- •unable to demonstrate an understanding of the informed consent
- •non-English speaking
- •reporting imminent risk of suicide
- •have an unstable psychiatric condition
- •currently involved in treatment for depression
- •recently started antidepression medication or outpatient treatment for anxiety or substance use disorder
- •currently involved or completed inpatient or intensive outpatient treatment
Outcomes
Primary Outcomes
Change From Baseline in Depressive Symptoms at 12 Weeks
Time Frame: Baseline and 12 weeks
The investigators will use the Patient Health Questionnaire-9 (PHQ-9) to assess depressive symptoms at baseline and 12 weeks. The minimum value is 0 and the maximum value is 27. Higher scores mean a worse outcome.
Secondary Outcomes
- Change From Baseline in the Level of Reward/Positive Mood When Engaging in Various Experiences at 12 Weeks(Baseline and 12 weeks)
- Change From Baseline in Quality of Life at 12 Weeks(Baseline and 12 weeks)
- Change From Baseline in Sleep Disturbances at 12 Weeks(Baseline and 12 weeks)